No Detail Found!

The Effects of Topiramate on Weight Gain in Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial

Author(s)
Hamidreza Jamilian Department of Psychiatry, Arak University of Medical Sciences,Arak,Iran
Mehran Shayganfard Department of Psychiatry, Arak University of Medical Sciences,Arak,Iran
Abstract
BACKGROUND: Weight gain among patients with schizophrenia is challenging. To evaluate the effects of topiramate on treatment of schizophrenia and weight gain management. METHODS: For this double-blind randomized placebo-controlled clinical trial; 59 patients at Arak University Hospital were recruited. In the control group (n=29) atypical antipsychotic agent equivalent to 20 mg of olanzapine was given while the intervention group (n=30) was treated with atypical antipsychotic equivalent to 20 mg of olanzapine and topiramate at dose of up to 200 mg for 12 weeks. The Positive And Negative Syndrome Scale (PANSS) and Body Mass Index (BMI) of patients were measured at baseline and during the study.and 28 females (47.5%) with mean age of 29.9±7.67 years (ranged 16.7-47.3 years) were randomized. In the two groups, total PANSS significantly decreased after 12- week therapy (P=0.001). BMI in the control group decreased by only 0.25% from baseline to week 12 and was not significant (p=0.69). In topiramate group, the reduction of BMI from baseline to week 12 was 8.3% and was statistically significant (26.67±3.51 to 24.47±3.55, P=0.001). The difference between the treatment and control groups regarding BMI in weeks 8 and 12 and PANSS in weeks 4, 8 and 12 was significant (P<0.05). CONCLUSION: Our results indicated that topiramate at a dose of 200 mg/day is a safe agent and induces weight loss and significantly decreases PANSS score in patients with schizophrenia.
Publication Details
Page(s) 55-59
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 8, Issue: 2, Year: 2018

Request the full text from PASTIC

Keywords
antipsychotic, Positive and Negative Syndrome Scale, Weight gain, Topiramate, Schizophrenia
References
Coodin S. .2001 .Body mass index in persons with schizophrenia. Can J Psychiatry, 46(6) : 549-555.
Brown S,Birtwistle J,Roe L .1999 .The unhealthy lifestyle of people with schizophrenia. Psychol Med, 29(3) : 697-701.
Allison DB,Mentore JL,Heo M .1999 .Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry, 156(11) : 1686-1696.
Biton V,Montouris GD,Ritter F .1999 .A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology, 52 : 1330-1337.
Chengappa KNR,Levine J,Rathore D .2001 .Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry, 16(3) : 186-190.
Gordon A,Price LH .1999 .Mood stabilization and weight loss with topiramate. Am J Psychiatry, 156(6) : 968-969.
Ben-Menachem E,Axelsen M,Johanson EH,Stagge A,Smith U .2003 .Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res, 11(4) : 556-562.
Arnone D . .2005 .Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry, 4(1) : 5.
Shank RP,Gardocki JF,Streeter AJ,Maryanoff BE .2000 .An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 41(Suppl 1) : S3-S9.
Ko YH,Joe SH,Jung IK,Kim SH .2005 .Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol, 28(4) : 169-175.
Lee C,Wu KH,Habil H,Dyachkova Y,Lee P,Aust N Z J Psychiatry P .2006 .Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. , 40(5) : 437-445.
Van AM,Mancini C .2002 .Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry, 63(11) : 981-984.
Li Z,Maglione M,Tu W .2005 .Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med, 142(7) : 532-546.
Aldenkamp AP,Baker G,Mulder OG G .2000 .A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia, 41 : 1167-1178.
Mousavi SG,Golchin SH,Afshar H .2007 .Add-On Topiramate In Treatment of Schizophrenia. Journal of Isfahan Medical School, 25 : .
Baptista T. .1999 .Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand, 100(1) : 3-16.
Dufresne RL,Valentino D,Kass DJ D .1993 .Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol Bull, 29(2) : 249-255.
Nemeroff CB .1997 .Dosing the antipsychotic medication olanzapine. J Clin Psychiatry, 58(Suppl 10) : 45-9.
Umbricht DSG,Pollack S,Kane JM,Suppl B .1994 .Clozapine and weight gain. J Clin Psychiatry, 55 : 157-60.
Ganguli R .1999 .Weight gain associated with antipsychotic drugs. J Clin Psychiatry, 60(Suppl 21) : 20-4.
Narula PK,Rehan HS,Unni K HS,Gupta N. .2010 .Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. Schizophr Res, 118(1-3) : 218-223.
Hahn MK,Remington G,Bois D,Cohn T. Topiramate .2010 .Augmentation in Clozapine-Treated Patients With Schizophrenia. J Clin Psychopharmacol, 30(6) : 706-710.
Lévy E,Agbokou C,Ferreri F,Chouinard G,Margolese HC .2007 .Topiramate induce weight loss in schizophrenia; A retrospective case series study. Can J Clin Pharmacol, 14(2) : 234-239.
Talaei A,Faridhoseini F,Kazemi H .2015 .Effect of topiramate on drug associated weight gain of patients with schizophrenia and bipolar I disorders: a dose ranging study. Turkish Journal of Psychiatry, 27(2) : .
Shapiro M,Reid A,Olsen B,Taasan M,McNamara J .2016 .Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: A medical record review. Int J Psychiatry Med, 51(1) : 56-68.
Behdani F,Hebrani P,Rezaei Ardani A,Rafee E .2011 .Effect of Topiramate Augmentation in Chronic Schizophrenia: A Placebo-Controlled Trial. Arch Iran Med, 14(4) : 270-275.
Banta JT,Hoffman K,Budenz DL .2001 .Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol, 132(1) : 112-114.
Kuo RL,Moran ME,Kim DH .2002 .Topiramateinduced nephrolithiasis. J Endourol, 16 : 229-231.
0

Citations

0

Downloads

7

Views